Breaking News Instant updates and real-time market news.

ALLY

Ally Financial

, GG

Goldcorp

09:40
07/18/17
07/18
09:40
07/18/17
09:40

Unusually active option classes on open July 18th

Unusual total active option classes on open include: Ally Financial (ALLY), Goldcorp (GG), IBM (IBM), Johnson & Johnson (JNJ), Amgen (AMGN), Goldman Sachs (GS), iShares Silver Trust (SLV), AMD (AMD), Twitter (TWTR), and Microsoft (MSFT).

ALLY

Ally Financial

GG

Goldcorp

IBM

IBM

JNJ

Johnson & Johnson

AMGN

Amgen

$177.40

0.27 (0.15%)

GS

Goldman Sachs

SLV

iShares Silver Trust

AMD

AMD

$13.80

-0.12 (-0.86%)

TWTR

Twitter

MSFT

Microsoft

$73.35

0.57 (0.78%)

  • 18

    Jul

  • 18

    Jul

  • 19

    Jul

  • 19

    Jul

  • 19

    Jul

  • 20

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Jul

  • 27

    Jul

  • 01

    Aug

  • 09

    Aug

  • 14

    Aug

  • 15

    Aug

  • 29

    Aug

  • 05

    Sep

  • 13

    Sep

  • 14

    Sep

  • 17

    Oct

  • 03

    Feb

ALLY Ally Financial

03/27/17
JANY
03/27/17
INITIATION
Target $23
JANY
Neutral
Ally Financial initiated with a Neutral at Janney Capital
Janney Capital analyst John Rowan started Ally Financial with a Neutral rating and $23 fair value estimate.
03/27/17
03/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) was initiated with an Outperform at William Blair, Cowen, RBC Capital, Credit Suisse, and JMP Securities, with a Perform at Oppenheimer, an Overweight at Morgan Stanley, a Buy at Jefferies, Citi, and Goldman, while being initiated with a Hold at Stifel, a Neutral at UBS, BofA/Merrill, and JPMorgan. 2. Starbucks (SBUX) initiated with an Outperform at Telsey Advisory. 3. Hamilton Lane (HLNE) initiated with an Overweight at Morgan Stanley and JPMorgan, a Market Perform at Wells Fargo and Keefe Bruyette, while Goldman intiated the stock with a Neutral. 4. MAA (MAA) initiated with an Overweight at Barclays. 5. Ally Financial (ALLY) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/09/17
PIPR
06/09/17
INITIATION
Target $25
PIPR
Overweight
Ally Financial initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Kevin Barker started Ally Financial with an Overweight rating and $25 price target. The analyst views the stock's risk/reward as one of the best within financials. The analyst sees a four-to-one upside/downside scenario for patient investors willing to wait for a slightly more favorable environment.
07/17/17
SPHN
07/17/17
DOWNGRADE
SPHN
Underweight
Ally Financial downgraded to Underweight from Equal Weight at Stephens
GG Goldcorp

07/12/17
MACQ
07/12/17
UPGRADE
MACQ
Outperform
Goldcorp upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Michael Siperco upgraded Goldcorp to Outperform citing valuation and expectations for better second half results.
03/16/17
RBCM
03/16/17
UPGRADE
RBCM
Sector Perform
Goldcorp upgraded on vaulation, operational progress at RBC Capital
As noted earlier, RBC Capital upgraded Goldcorp to Sector Perform from Underperform. Analyst Stephen Walker upgraded the stock based on valuation and the progress the company has made with a number of its major projects. Target to $17 from $15.
03/16/17
RBCM
03/16/17
UPGRADE
Target $17
RBCM
Sector Perform
Goldcorp upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital analyst Stephen Walker Stephen Walker upgraded Goldcorp to Sector Perform with a $17 price target.
03/29/17
RODM
03/29/17
DOWNGRADE
Target $1.75
RODM
Neutral
Exeter Resource downgraded to Neutral from Buy at Rodman & Renshaw
Rodman & Renshaw analyst Heiko Ihle downgraded Exeter Resource (XRA citing the takeover by Goldcorp (GG). The analyst believes additional bidders are unlikely. He has a $1.75 price target for the shares.
IBM IBM

06/22/17
CLVD
06/22/17
INITIATION
CLVD
Neutral
IBM initiated with a Neutral at Cleveland Research
Cleveland Research initiated IBM with a Neutral with a $154 price target saying channel sentiment has improved over the last six months driven by better installed base retention and wallet share gains from cloud and software as a service offerings. The analyst is slightly ahead of consensus for earnings through FY19 and said there could be some upside to revenue assumptions should Services stabilize adn partner growth outlooks materialize.
07/10/17
KEYB
07/10/17
NO CHANGE
KEYB
IT services companies can benefit from AI opportunity, says KeyBanc
KeyBanc analyst Arvind Ramnani says that IT services companies such as Cognizant (CTSH), Accenture (ACN) and IBM (IBM) can benefit significantly as enterprises look to access data in order to enable artificial intelligence. The analyst adds that Talend's (TLND) data integration tools can also benefit from this trend. He keeps Overweight ratings on all the stocks named, except that he keeps a Sector Weight rating on IBM.
07/12/17
JEFF
07/12/17
NO CHANGE
Target $125
JEFF
Underperform
IBM price target lowered to $125 from $135 at Jefferies
Jefferies analyst James Kisner lowered his price target for IBM (IBM) to $125 and reiterates an Underperform rating on the shares. While channel checks indicate IBM's Watson platform remains one of the most complete cognitive platforms available in the marketplace today, the "hefty services" component of many artificial intelligence deployments will be a hindrance to adoption, Kisner tells investors in a research note titled "Creating Shareholder Value with AI? Not so Elementary, My Dear Watson." The analyst also believes IBM looks "outgunned in the war" for AI talent and will likely see increasing competition. Kisner adds that his firm believes Nvidia (NVDA) is the biggest beneficiary of ramping AI adoption. He lists Pure Storage (PSTG) and Mellanox (MLNX) as other beneficiaries.
07/17/17
LEHM
07/17/17
NO CHANGE
Target $132
LEHM
Underweight
Barclays calls on IBM to cut outlook, drops price target to $132
IBM should take the "brave step" and drastically reset its full-year earnings per share outlook to $13.00 or lower, Barclays analyst Mark Moskowitz tells investors in a research note. He believes the company's narrative is "becoming tedious" with a lot of investments in next-generation technology generating little revenue impact. The analyst cut his below-consensus estimates for 2017 and 2018 and dropped his price target for IBM shares to $132 from $141. The technology company closed Friday up 61c to $154.24. Moskowitz keeps an Underweight rating on the shares. He views IBM's valuation as "stretched" and does not think cost cuts will be enough to counter increasing exposure to cloud-related or "as-a-service" revenue that carries lower revenue and profit.
JNJ Johnson & Johnson

06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $10
ADAM
Buy
Novadaq competing bids possible if not probable, says Canaccord
Canaccord analyst Jason Mills noted Novadaq (NVDQ) received an acquisition offer from Stryker (SYK) at a much greater equity value than what the company was trading at prior to the bid. Although he thinks Stryker is the most logical buyer of the franchise, he thinks there are several other potential acquirers, including Medtronic (MDT), Johnson & Johnson (JNJ) and Intuitive Surgical (ISRG), in that order. Mills believes this is a good exit for the company and that Stryker is getting a good asset. Mills maintains his Buy rating and $10 price target on Novadaq shares.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
AMGN Amgen
$177.40

0.27 (0.15%)

07/17/17
JEFF
07/17/17
NO CHANGE
Target $195
JEFF
Buy
Amgen Complete Response Letter was expected, says Jefferies
Jefferies analyst Michael Yee says the FDA's Complete Response Letter for Amgen's Romosozumab in osteoporosis was expected. The indication is not in current consensus near-term estimates given the prior known imbalance in safety signal, Yee tells investors in a research note. He believes the drug could still be approved in 2018-2019 based on a good risk/benefit profile. The analyst has a Buy rating on Amgen with a $195 price target.
07/18/17
CHLM
07/18/17
NO CHANGE
Target $160
CHLM
Buy
Craig-Hallum sees Ligand agreement with Amgen as 'incrementally' positive news
Craig-Hallum analyst Matt Hewitt notes that Ligand (LGND) announced that it had entered into a new commercial license and supply agreement with Amgen (AMGN) for the use of the former's Captisol technology in the formulation of AMG 330, a bispecific antibody being investigated as a treatment for acute myeloid leukemia. The analyst believes this agreement signals AMG 330 moving from Phase 1 into Phase 2 trials and incrementally positive news for Ligand as this news was not anticipated in his model. Hewitt reiterates a Buy rating and $160 price target on Ligand's shares.
07/10/17
JEFF
07/10/17
INITIATION
Target $195
JEFF
Buy
Amgen assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage on Amgen with a Buy and a $195 price target.
06/23/17
06/23/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Starbucks (SBUX) initiated with an Overweight at KeyBanc. 2. Wix.com (WIX) initiated with an Outperform at Wedbush. 3. Red Hat (RHT) initiated with a Neutral at Piper Jaffray. 4. Amgen (AMGN) initiated with a Hold at Deutsche Bank. 5. Oclaro (OCLR) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
GS Goldman Sachs

06/02/17
NOMU
06/02/17
NO CHANGE
NOMU
Goldman Sachs, Morgan Stanley Q2 EPS estimates lowered at Nomura Instinet
Nomura Instinet analyst Steven Chubak cut his Q2 EPS estimate for Goldman Sachs (GS) to $3.50 from $4.04 and lowered his Q2 EPS estimate for Morgan Stanley (MS) to 77c from 86c. The consensus EPS estimates for Goldman and Morgan Stanley are $3.92 and 84c, respectively. Chubak says that Goldman has been hurt by "weaker trading and more pronounced (investment banking) declines," while Morgan Stanley is experiencing "softer" investment banking results and "more pronounced quarter-over-quarter" fixed income declines. He keeps a Neutral rating on Goldman and a Buy rating on Morgan stanley.
06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
06/28/17
FBCO
06/28/17
NO CHANGE
Target $240
FBCO
Outperform
Goldman Sachs price target raised to $240 from $230 at Credit Suisse
Credit Suisse analyst Susan Roth Katzke lowered her 2017 estimates for Goldman Sachs to reflect the current low volume/low volatility trading environment. However, assuming capital markets growth follows macroeconomic growth and the company realizes incremental operating leverage, she increased her 2018 and 2019 estimates for Goldman. Katzke increased her price target on Goldman shares to $240 from $230 and keeps an Outperform rating on the stock.
04/20/17
04/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Starbucks (SBUX) upgraded to Buy from Hold at Stifel with analyst Mark Astrachan saying he views valuation as attractive and expects multiple expansion from accelerating U.S. comparable store sales growth to at least 5%-6% for the next four quarters starting in the June quarter. The analyst said shares have underperformed consumer and restaurant peers over the past 12 months and expects outperformance to be driven by meeting comp expectations. 2. Goldman Sachs (GS) upgraded to Overweight from Neutral at Atlantic Equities with analyst Christopher Wheeler telling investors investors shares are "oversold." The analyst expects the FICC business to bounce back and made just a small reduction in estimates to account for further cost measures. 3. Lear (LEA) upgraded to Outperform from Neutral at Baird with analyst David Leiker citing its recent underperformance despite improving fundamentals and a strong global auto backdrop. Leiker raised his price target to $161 from $160 on Lear shares. 4. Discovery (DISCA) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying he sees little chance of material downward revisions to consensus earnings estimates. The analyst views the risk/reward as more balanced at current levels and upped his price target for the shares to $30 from $27. 5. Gap (GPS) upgraded to Neutral from Underweight at JPMorgan with analyst Matthew Boss citing the underperformance of the shares over the past 18 months and his fieldwork which suggests stability at Old Navy. The analyst raised his price target for the shares to $24 from $21. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SLV iShares Silver Trust

AMD AMD
$13.80

-0.12 (-0.86%)

07/18/17
BMOC
07/18/17
NO CHANGE
BMOC
AMD outlook mixed, says BMO Capital
BMO Capital analyst Ambrish Srivastava says he is "a bit cautious" on AMD (AMD) heading into its results as he believes that crypto mining demand and profitability "could collapse." However, the analyst remains upbeat on AMDs longer term outlook, as he thinks that it can deliver "consistent execution in its emerging product areas" and gain share from Intel (INTC) and Nvidia (NVDA). He keeps an Outperform rating on AMD.
07/10/17
JPMS
07/10/17
NO CHANGE
JPMS
JPMorgan raises semiconductor market forecasts after strong May
JPMorgan analyst Hisashi Moriyama attributes data center demand due to the spread of cloud computing and expanding applications for Internet of Things as driving better than expected May growth in the semiconductor market. The analyst, who also believes growth to the automobile market is accelerating, raised his semiconductor market forecasts given the strong May. Publicly traded companies in the semiconductor space include AMD (AMD), Intel (INTC), Marvell (MRVL), Microchip (MCHP), Micron (MU), Nvidia (NVDA), Qualcomm (QCOM) and Texas Instruments (TXN).
07/18/17
LEHM
07/18/17
DOWNGRADE
Target $9
LEHM
Underweight
AMD downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Blayne Curtis downgraded AMD (AMD) to Underweight with an unchanged price target of $9. The chipmaker closed yesterday down 12c to $13.80. The analyst is "unconvinced" that AMD products will gain enough traction to support the current valuation. He also has difficulty "getting anywhere near" the company's long-term earnings per share target of 75c. Curtis likes shares of Cavium (CAVM) and Cypress Semiconductor (CY) in the U.S. Semiconductors space heading into Q2 earnings.
07/18/17
LEHM
07/18/17
UPGRADE
Target $60
LEHM
Equal Weight
Xilinx upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Blayne Curtis upgraded Xilinx (XLNX) to Equal Weight saying he sees more downside elsewhere in the U.S. Semiconductors space. The analyst raised his price target for the shares to $60 from $53. The analyst this morning downgraded both AMD (AMD) and Cirrus Logic (CRUS) to Underweight.
TWTR Twitter

07/13/17
OTRG
07/13/17
UPGRADE
OTRG
Mixed
Twitter upgraded to Mixed from Negative at OTR Global
07/13/17
STFL
07/13/17
UPGRADE
Target $22
STFL
Buy
Stifel upgrades Snap to Buy on 'compelling' post-selloff opportunity
Stifel analyst Scott Devitt upgraded Snap (SNAP) to Buy from Hold with a $22 price target. The shares closed yesterday down 23c to $15.24. Following the recent selloff on the Q1 revenue miss, concerns over the company's lock-up event beginning in late July and increased competition from Facebook's (FB) Instagram, Snap shares offer a "compelling risk/reward opportunity," Devitt tells investors in a research note partially titled "Relishing the Opportunity." Near-term risks to revenue-generating daily active users may be overstated as recent app download trends "appear healthy" in key advertising markets, the analyst adds. He believes Snap's business "remains on track fundamentally" despite the market concerns and "persistent" comparisons to Twitter (TWTR). Piper Jaffray this morning cut Snap's price target to $16.50 on concerns over competition from Instagram.
07/13/17
07/13/17
UPGRADE

Mixed
Twitter upgraded to Mixed on growth stabilization at OTR Global
As previously reported, OTR Global upgraded Twitter to Mixed from Negative. Analyst Phil Leggiere said Q2 year-over-year ad spending on Twitter picked up to 2%-5%, versus Q1 of flat-up slightly, on lower pricing, and more available inventory. He expects Q3 spending to be up 2%-5% year-over-year and said direct-response advertisers are attracted to Twitters wider reach, targeting improvements, and better ROI.
07/13/17
STPT
07/13/17
DOWNGRADE
STPT
Hold
Twitter downgraded to Hold from Reduce at Standpoint Research
MSFT Microsoft
$73.35

0.57 (0.78%)

07/13/17
CLVD
07/13/17
NO CHANGE
CLVD
Buy
Microsoft annual partner conference made Cleveland Research more bullish
Cleveland Research said it is now more bullish on Microsoft following discussions on the heels of the company's annual partner conference, Inspire, as feedback was positive on the company's sales reorganization and several catalysts were pointed to as likely to accelerate Azure share gains.
07/18/17
GSCO
07/18/17
NO CHANGE
Target $88
GSCO
Microsoft price target raised to $88 from $78 at Goldman Sachs
Goldman analyst Heather Bellini raised Microsoft's price target to $88 from $78 and reiterated its Buy rating ahead of Q4 results on Thursday. The analyst sees potential upside to earnings and revenues driven by strength in Cloud offerings, and notes Azure field checks have been very strong indicating a potential to reaccelerate.
07/17/17
BOFA
07/17/17
NO CHANGE
Target $83
BOFA
Buy
Microsoft price target raised to $83 from $75 at BofA/Merrill
BofA/Merrill analyst Kash Rangan raised Microsoft's price target to $83 from $75 and reiterated his Buy rating. The analyst expects the company to report Q4 earnings of 72c, versus consensus of 71c, and revenue of $24.5B, versus consensus of $24.3B and said the company has multiple gross margin drivers and is at an inflection in large TAM markets.
07/17/17
FBCO
07/17/17
NO CHANGE
Target $84
FBCO
Outperform
Microsoft Azure momentum could accelerate, says Credit Suisse
Credit Suisse analyst Michael Nemeroff says his firm's recent enterprise software survey suggests that demand for Microsoft's Azure could be at a positive inflection point. The analyst reiterates an Outperform rating on the shares, while raising his price target for the stock to $84 from $80 ahead of Q4 results.

TODAY'S FREE FLY STORIES

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

16:30
10/18/17
10/18
16:30
10/18/17
16:30
Earnings
Crown Castle sees FY18 AFFO $2.22B-$2.26B »

Sees FY18 site rental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
10/18/17
10/18
16:30
10/18/17
16:30
Options
Preliminary option volume of 16.8M today »

Preliminary option volume…

RXDX

Ignyta

$16.25

1.9 (13.24%)

16:29
10/18/17
10/18
16:29
10/18/17
16:29
Syndicate
Ignyta announces $125M common stock offering »

Ignyta anticipates using…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 06

    Nov

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

16:28
10/18/17
10/18
16:28
10/18/17
16:28
Earnings
Crown Castle sees Q4 AFFO $430M-$435M »

Sees Q4 site rental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGI

Pattern Energy

16:28
10/18/17
10/18
16:28
10/18/17
16:28
Syndicate
Pattern Energy files to sell 8M shares of Class A common stock »

The offering is being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USAP

Universal Stainless & Alloy

$21.12

-0.33 (-1.54%)

16:27
10/18/17
10/18
16:27
10/18/17
16:27
Hot Stocks
Breaking Hot Stocks news story on Universal Stainless & Alloy »

Universal Stainless &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDN

Brandywine Realty

$17.93

-0.02 (-0.11%)

16:26
10/18/17
10/18
16:26
10/18/17
16:26
Hot Stocks
Brandywine Realty announces joint venture disposition »

"In addition to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 14

    Dec

RXDX

Ignyta

$16.25

1.9 (13.24%)

16:25
10/18/17
10/18
16:25
10/18/17
16:25
Syndicate
Breaking Syndicate news story on Ignyta »

Ignyta files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 06

    Nov

NTB

Butterfield

$35.81

0.29 (0.82%)

16:25
10/18/17
10/18
16:25
10/18/17
16:25
Hot Stocks
Butterfield chief risk officer Frumkin named COO »

The Bank of N.T.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 15

    Nov

VSEC

VSE Corp.

$58.21

0.01 (0.02%)

16:25
10/18/17
10/18
16:25
10/18/17
16:25
Hot Stocks
VSE Corp. awarded $35.6M in new delivery order awards »

VSE Corporation was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$153.00

2.62 (1.74%)

16:25
10/18/17
10/18
16:25
10/18/17
16:25
Conference/Events
Adobe to hold a briefing »

Financial Analyst and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 06

    Nov

HXL

Hexcel

$58.94

0.39 (0.67%)

16:24
10/18/17
10/18
16:24
10/18/17
16:24
Earnings
Hexcel narrows FY17 EPS guidance to $2.64-$2.72 from $2.64-$2.76 »

Consensus $2.68. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAL

United Continental

$67.99

0.48 (0.71%)

16:24
10/18/17
10/18
16:24
10/18/17
16:24
Hot Stocks
United Continental says Q3 pre-tax income reduced by about $185M due to storms »

During the quarter, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

BDN

Brandywine Realty

$17.93

-0.02 (-0.11%)

16:24
10/18/17
10/18
16:24
10/18/17
16:24
Earnings
Brandywine Realty sees FY18 EPS of 34c-44c, consensus 25c »

Announces 2018 FFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 14

    Dec

CCI

Crown Castle

$101.03

-0.315 (-0.31%)

16:23
10/18/17
10/18
16:23
10/18/17
16:23
Earnings
Crown Castle reports Q3 adjusted EPS 21c, consensus 24c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSC

TriState Capital

$22.75

-0.2 (-0.87%)

16:23
10/18/17
10/18
16:23
10/18/17
16:23
Earnings
TriState Capital reports Q3 EPS 35c, consensus 30c »

Reprots Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

TBK

Triumph Bancorp

$31.80

0.25 (0.79%)

16:23
10/18/17
10/18
16:23
10/18/17
16:23
Earnings
Triumph Bancorp reports Q3 EPS 47C, consensus 44C »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 15

    Nov

BDN

Brandywine Realty

$17.93

-0.02 (-0.11%)

16:23
10/18/17
10/18
16:23
10/18/17
16:23
Earnings
Brandywine Realty raises FY17 EPS view to 72c-74c from 17c-21c »

Consensus 24c. Adjusting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 14

    Dec

HXL

Hexcel

$58.94

0.39 (0.67%)

16:22
10/18/17
10/18
16:22
10/18/17
16:22
Earnings
Hexcel reports Q3 EPS 71c, consensus 68c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.97

0.48 (1.28%)

16:22
10/18/17
10/18
16:22
10/18/17
16:22
Hot Stocks
eBay added 2M active buyers in Q3 »

In the third quarter,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BPFH

Boston Private Financial

$16.50

0.2 (1.23%)

16:22
10/18/17
10/18
16:22
10/18/17
16:22
Earnings
Boston Private Financial reports Q3 EPS 22c, consensus 23c »

Average total deposits…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

, BRK.A

Berkshire Hathaway

$281,290.00

240 (0.09%)

16:22
10/18/17
10/18
16:22
10/18/17
16:22
Hot Stocks
American Express says Squeri to succeed retiring Chenault as CEO »

American Express (AXP)…

AXP

American Express

$92.08

0.39 (0.43%)

BRK.A

Berkshire Hathaway

$281,290.00

240 (0.09%)

BRK.B

Berkshire Hathaway

$187.85

0.46 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

EBAY

eBay

$37.97

0.48 (1.28%)

16:22
10/18/17
10/18
16:22
10/18/17
16:22
Hot Stocks
Breaking Hot Stocks news story on eBay »

eBay reports Q3 Gross…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRS

Verso

$6.00

0.2 (3.45%)

16:21
10/18/17
10/18
16:21
10/18/17
16:21
Hot Stocks
Breaking Hot Stocks news story on Verso »

Mudrick Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EBAY

eBay

$37.97

0.48 (1.28%)

16:21
10/18/17
10/18
16:21
10/18/17
16:21
Earnings
eBay sees FY17 EPS $1.99 - $2.01, consensus $2.00 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.